Literature DB >> 21763966

The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.

Jose A Karam1, Christopher G Wood.   

Abstract

Renal cell carcinoma (RCC) is considered a relatively rare malignancy worldwide. Around a third of patients with RCC present with metastatic disease, and among those patients treated with nephrectomy with curative intent, more than one-third develop metastases during postoperative follow-up. Due to the absence of curative medical treatments for metastatic RCC, surgery remains the mainstay of therapy. Surgery plays a key role in two aspects: cytoreductive nephrectomy to remove the primary renal tumor in the presence of known metastatic disease, and metastasectomy to remove distant metastatic foci in patients with metastatic RCC.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763966     DOI: 10.1016/j.hoc.2011.05.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  6 in total

Review 1.  Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Authors:  Paul L Crispen; Michael L Blute
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

Authors:  Michael A Feuerstein; Matthew Kent; Wassim M Bazzi; Melanie Bernstein; Paul Russo
Journal:  World J Urol       Date:  2014-01-09       Impact factor: 4.226

3.  Metachronous adrenal metastasis from operated contralateral renal cell carcinoma with adrenalectomy and iatrogenic Addison's disease.

Authors:  Hakan Ozturk; Serap Karaaslan
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

4.  Bilateral synchronous adrenal metastases of renal cell carcinoma: A case report and review of the literature.

Authors:  Hakan Öztürk
Journal:  Oncol Lett       Date:  2015-01-28       Impact factor: 2.967

5.  Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Authors:  Brian I Rini; David F McDermott; Hans Hammers; William Bro; Ronald M Bukowski; Bernard Faba; Jo Faba; Robert A Figlin; Thomas Hutson; Eric Jonasch; Richard W Joseph; Bradley C Leibovich; Thomas Olencki; Allan J Pantuck; David I Quinn; Virginia Seery; Martin H Voss; Christopher G Wood; Laura S Wood; Michael B Atkins
Journal:  J Immunother Cancer       Date:  2016-11-15       Impact factor: 13.751

6.  Gastrointestinal Involvement of Recurrent Renal Cell Carcinoma: CT Findings and Clinicopathologic Features.

Authors:  Hyo Jung Park; Hyun Jin Kim; Seong Ho Park; Jong Seok Lee; Ah Young Kim; Hyun Kwon Ha
Journal:  Korean J Radiol       Date:  2017-04-03       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.